Searchable abstracts of presentations at key conferences on calcified tissues

ba0007p25 | (1) | ICCBH2019

Short term mechanical stimulation using whole body vibration identifies differences in bone response between prepubertal boys with and without prior fracture

Harrison Rachel , Ward Kate , Rigby Alan , Gossiel Fatma , Bishop Nick

Objectives: Previously we have shown in healthy pre-pubertal boys that short periods of whole body vibration (WBV) increased the bone formation marker PINP by 25.1% and resorption marker CTX by 10.9%. The aim of this study was to see if otherwise healthy boys with a history of fracture would respond to WBV in the same way.Methods: In addition to 11 pre-pubertal boys measured previously in the same way, 20 pre-pubertal boys aged 7-13 years, who were at le...

ba0003oc6.5 | Osteoporosis treatment and the effects of physical activity | ECTS2014

The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal women with rsteoporosis: The TRIO study

Gossiel Fatma , Hoyle Christopher , McCloskey Eugene , Walsh Jennifer , Peel Nicola , Eastell Richard

Bisphosphonates are used to treat bone disease characterised by increased bone resorption by inhibiting the activity of mature osteoclasts, resulting in decreased bone turnover. Bisphosphonates may reduce the population of osteoclast precursor cells (OPCs). Our aims were to investigate the effect of bisphosphonates on i) OPCs and ii) bone turnover in postmenopausal women with osteoporosis compared with healthy premenopausal women. Participants were 62 postmenopausal women (mea...

ba0003pp306 | Osteoporosis: treatment | ECTS2014

The effect of bisphosphonate treatment on sclerostin levels in postmenopausal osteoporosis: the TRIO study

Gossiel Fatma , Naylor Kim , McCloskey Eugene , Peel Nicola , Walsh Jennifer , Paggiosi Margaret , Eastell Richard

Treatment of postmenopausal osteoporosis with bisphosphonates reduces bone resorption and formation. Sclerostin, an osteocyte regulator of bone formation may be involved in these changes. Some studies have reported an increase in sclerostin associated with bisphosphonate treatment while others have reported a decrease. The aims were to determine the effect of bisphosphonates on i) circulating sclerostin and ii) PINP in postmenopausal women with osteoporosis. We studied 92 post...

ba0003pp330 | Osteoporosis: treatment | ECTS2014

Determinants of bone turnover marker response to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

Naylor Kim , Paggiosi Margaret , Gossiel Fatma , McCloskey Eugene , Peel Nicola , Walsh Jennifer , Eastell Richard

Three oral bisphosphonates ibandronate, alendronate, and risedronate are commonly used for the treatment of osteoporosis but they have not previously been compared in the same study. Our aim was to identify determinants of change in bone turnover markers (BTM) in response to these bisphosphonates in a 2-year randomised parallel group trial. We recruited 171 postmenopausal osteoporotic women (<85 years) who were randomised to receive ibandronate (150 mg monthly), alendronat...

ba0005oc3.4 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

The response of fibroblast growth factor-23 to teriparatide in postmenopausal osteoporosis

Gossiel Fatma , McCloskey Eugene , Walsh Jennifer , Naylor Kim , Peel Nicola , Eastell Richard

FGF-23 is a phosphate regulating hormone and its production may be stimulated by circulating levels of 1,25-dihydroxyvitamin D (1,25-(OH)2D). Teriparatide administration increases levels of 1,25-(OH)2D, however it is unclear whether this mediates changes in FGF-23 levels. The aims were i) to determine the effect of teriparatide treatment on circulating levels of FGF-23 and 1,25-(OH)2D and ii) to describe the time course of effect in postmenopau...

ba0005p97 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2016

Vitamin D therapy: the effects of race, skin colour and genotype

Sujatha Jaya , Kothandapani Gopal , Evans Lucy , Fatma Gossiel , Walsh Jennifer , Eastell Richard , Bishop Nick

Background: It is well established that Asians have lower levels of vitamin D (25OHD) when compared to Caucasians. Vitamin D binding protein (DBP) levels are also lower in some races than in Caucasians.Objectives: i) To find out whether DBP is lower in Asians; ii) To find out whether free 25OHD is lower in Asians; iii) To find out whether PTH is increased in Asians and interpret this in relation to 25OHD levels and iv) To find out whether the increment i...

ba0007p27 | (1) | ICCBH2019

Response to mechanical stimulation of bone in children with osteogenesis imperfecta and the effect of bisphosphonate therapy

Sithambaran Sivagamy , Gopal Sujatha , Harrison Rachel , Gossiel Fatma , Rigby Alan , Bishop Nick

Objectives: Children with osteogenesis imperfecta (OI) suffer fragility fractures due to altered bone mass, architecture and material quality. Management is multidisciplinary, often including bisphosphonates and physiotherapy. We wished to determine whether bisphosphonates altered the skeletal response to mechanical stimulation in OI. Short term exposure to whole body vibration (WBV) in apparently healthy children results in increases in bone formation and resorption markers, ...

ba0007p133 | (1) | ICCBH2019

Losartan reduces circulating TGFb and CTX and increases vertebral bone mass in the OIM mouse

Bishop Nick , Kalajzic Ivo , Arshad Fawaz , Lefley Diane , Gossiel Fatma , Ottewell Penny

Objectives: Losartan is an angiotensin II receptor type 1 (AT1) antagonist. Losartan reduces circulating TGFb concentrations in a variety of myopathic models. We hypothesised that losartan administration to the murine osteogenesis imperfecta model OIM would result in lower circulating TGFb and CTX (bone resorption marker) and increase bone mass.Methods: All procedures were approved by UConn Health Institutional Animal Care and Use Committee and performed...

ba0003oc6.3 | Osteoporosis treatment and the effects of physical activity | ECTS2014

Vitamin D is low in obesity, and this is due to greater volume of distribution

Walsh Jennifer S , Evans Amy L , Bowles Simon , Naylor Kim E , Gossiel Fatma , Jacques Richard , Schoenmakers Inez , Jones Kerry S , Eastell Richard

Low circulating levels of total 25-hydroxyvitamin D (25OHD) have been reported in obese people of different ethnicities in several countries. Low total 25OHD in obesity could be due to lower binding proteins (with normal free 25OHD), lower dietary intake or sunlight exposure, greater volume of distribution (pool size) or more rapid metabolic clearance.The aims of this study were to determine if free 25OHD and 1,25-dihydroxyvitamin D (1,25(OH)2...